Takeda prepares to forge the Actos abyss
This article was originally published in Scrip
Executive Summary
Takeda is forecasting a precipitous drop in operating profit this fiscal year, hit mainly by the upcoming loss of US exclusivity for its top product, the oral antidiabetic Actos (pioglitazone).